BioSpace News Archive

Epic Sciences, Inc. announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois.

Viracta Therapeutics, Inc. announced that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL.

First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3rd

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the latest research from its robust oncology portfolio and pipeline to be presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago from May 31 to June 4.

Verastem, Inc. announced a poster highlighting dose modification data from the Phase 3 DUO study evaluating COPIKTRA (duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.

Medicure Inc., a pharmaceutical company, announced the appointment of Manon Harvey CPA, CA, to the Board of Directors.

Study Data Demonstrate That First-of-its-Kind Disease Modifying Investigational Therapy Significantly Reduces Plaque in Coronary Arteries and Increases Preß-HDL Particle Levels in Patients

Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors

Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary photoimmunotherapy platform, will be presenting data from its Phase 2a clinical trial focused on RM-1929 PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma during the ASCO annual meeting, May 31 – June 4, 2019 in Chicago.

BerGenBio ASA notes the publication of abstracts relating to new interim clinical and biomarker data that the company and its collaborators will present from its extensive Phase II clinical development programme with bemcentinib at the 2019 annual meeting of the American Society of Clinical Oncology at McCormick Place in Chicago, Illinois.